Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06402851 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Vitamin K AntagonISt, Factor Xa Inhibitor or No Anticoagulation in Atrial Fibrillation and DIalytic End-stage Renal DiseasE (VISIONAIRE)

Study acronym: VISIONAIRE
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Start date changed from estimate of Jul 2024 to Dec 18, 2024
    • Study sites: 0 to 6
    • Eligibility criteria expanded, about 14 words
    • Study title expanded, about 1 word
  2. Interventions: Oral anticoagulant (Drug) to Anticoagulant Oral (Drug)v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
VISIONAIRE (Vitamin K AntagonISt, Factor Xa Inhibitor Or Nothing In Atrial Fibrillation And DIalytic End-stage Renal DiseasE) trial will be a prospective randomized open-label with blinded endpoint adjudication trial including 1500 patients with atrial fibrillation or atrial flutter and advanced chronic kidney disease
Trial Details
NCT Number NCT06402851
Lead Sponsor Hospital Sirio-Libanes
Collaborators: Daiichi Sankyo
Conditions
(from sponsor)		 Atrium; Fibrillation, Chronic Kidney Diseases
Related terms Atrial Fibrillation, Atrial Flutter, Renal Insufficiency, Chronic
Enrollment 1,500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov